Washington, D.C. — Taking aim at high medication prices, President Donald J. Trump unveiled a new Executive Order aimed at aligning U.S. prescription drug costs with those in other nations. The move is part of Trump’s ongoing initiative to address the disparity between American drug prices and those paid abroad.

The Executive Order directs the U.S. Trade Representative and the Secretary of Commerce to investigate and take necessary measures against foreign practices that artificially depress market prices, subsequently leading to increased costs for American consumers. This action is intended to underscore the United States’ position as the largest purchaser of prescription drugs globally, with the aim of securing better pricing from pharmaceutical manufacturers.

Additionally, the Order mandates that the Secretary of Health and Human Services establish a mechanism allowing American patients to purchase medications directly from manufacturers at a “Most-Favored-Nation” rate, thereby eliminating intermediary costs that inflate retail prices. In cases where pharmaceutical companies do not adhere to this pricing model, the Secretary is empowered to propose rules enforcing this standard and to implement other strategies designed to decrease drug costs for consumers and combat anti-competitive practices.

This latest initiative underscores Trump’s commitment to reducing the financial burden on Americans seeking essential medications. Recent studies indicate that the average price of brand-name drugs in the U.S. is more than three times higher than that of other developed countries, even when discounts are factored in. Despite representing about five percent of the global population, the U.S. funds nearly three-quarters of worldwide pharmaceutical profits.

Drug companies often exploit the higher prices in the U.S. market to compensate for discounts provided abroad, effectively shifting the financial burden onto American patients. This practice has drawn considerable criticism, as it occurs alongside substantial government support for drug research and healthcare spending.

During his first term, Trump implemented measures aimed at preventing Medicare and seniors from being charged more than those in comparable countries, a policy that was rescinded by the current administration before it could take effect. Critics of the Biden Administration assert that it has made little progress on drug pricing, with negotiations reportedly yielding average prices that exceed those in eleven other similarly situated countries.

In continuing his pledge to prioritize American consumers, Trump is expanding efforts not only for Medicare but also for Medicaid, intending to lower drug prices across a broader spectrum of the population. Recently, he signed additional Executive Orders aimed at significantly increasing affordability for low-income patients and enhancing the availability of generic alternatives.

Moreover, the administration is pursuing transparency in drug pricing, reflecting a commitment to help consumers understand and navigate the complexities of medication costs. Trump’s initiatives in this area have included previous actions that aimed to eliminate hidden fees and encourage clear pricing structures in the pharmaceutical market.

As American patients grapple with soaring medication expenses, Trump’s latest Executive Order marks another step toward addressing these challenges and ensuring that they receive fair pricing for the essential medications they need.